New Drug: Dostarlimab for Endometrial Cancer
Study
Multicenter, multicohort, open-abel trial (GARNET)
|
dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen
|
Dostarlimab-gxly q21 (n=141)
|
Efficacy
ORR: 45.4% [37.0-54.0]; CR: 15.6%; PR:29.8%
|
12 mos DOR: 85.9%
|
24 mos DOR: 54.7%
|
Safety
Any grade AEs: Asthenia (40%), diarrhea (25%), anemia (25%), neutropenia (12%), skin rash (14%)
|
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer l
Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023
